Physician profile
Ted J Fish
NPI 1053375857
$2,182.39
in general payments reported to CMS, 2019-2025
24 companies · $24.10 in 2025
The $24.10 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,739 · 2020: $191 · 2021: $143 · 2022: $85.28 · 2025: $24.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $24.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $24.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $357.47 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $316.37 | 2019-2021 | |
| Pfizer INC. | $212.51 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $205.33 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $192.95 | 2019-2022 | |
| Amarin Pharma, INC. | $183.70 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $160.89 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.46 | 2019-2020 | |
| Regeneron Healthcare Solutions, INC. | $65.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.87 | 2019 | |
| Irhythm Technologies, INC. | $43.89 | 2019 | |
| Lundbeck LLC | $40.28 | 2019 | |
| Boston Scientific Corporation | $33.49 | 2019 | |
| Astellas Pharma US INC | $28.88 | 2019 | |
| Bardy Diagnostics, INC. | $26.53 | 2019-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.06 | 2019 | |
| Abbott Laboratories | $24.10 | 2025 | Cardiomems |
| Kowa Pharmaceuticals America, INC. | $23.80 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $22.18 | 2022 | |
| Merck Sharp & Dohme LLC | $16.51 | 2021 | |
| Vifor Pharma, INC. | $15.11 | 2019 | |
| Chiesi USA, INC. | $14.05 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.93 | 2022 | |
| Gilead Sciences, INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ted Fish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.